Literature DB >> 18855653

NK cell function in HIV-1 infection.

Andrea De Maria1, Lorenzo Moretta.   

Abstract

The parallel development of precise knowledge on NK cell receptors and on their function has considerably supported our understanding of the extension of their involvement during HIV-1 infection. The relevant reduction of NK cell function is dependent on well-described perturbations of their expression of specific receptors, leading not only to inhibition of their patrolling activity against invading pathogens, but also to alterations of their crosstalk with other cells of the immune system. With NK cell failure, boosted viral replication reduces immune surveillance towards opportunistic neoplasm and impaired control of adaptive responses prevails. NK cell function in human and animal models showing efficient control of disease progression may offer new insights in mechanisms underlying the protection from infectious disease.

Entities:  

Mesh:

Year:  2008        PMID: 18855653     DOI: 10.2174/157016208785861221

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  12 in total

1.  Higher NK cell IFN-γ production is associated with delayed HIV disease progression in LTNPs.

Authors:  Yongjun Jiang; Fangyuan Zhou; Yao Tian; Zining Zhang; Rongmei Kuang; Jing Liu; Xiaoxu Han; Qinghai Hu; Junjie Xu; Hong Shang
Journal:  J Clin Immunol       Date:  2013-09-03       Impact factor: 8.317

2.  Activation receptor-induced tolerance of mature NK cells in vivo requires signaling through the receptor and is reversible.

Authors:  Fred D Bolanos; Sandeep K Tripathy
Journal:  J Immunol       Date:  2011-01-24       Impact factor: 5.422

Review 3.  Immunoglobulin-like receptors and the generation of innate immune memory.

Authors:  Mouhamad Al-Moussawy; Hossam A Abdelsamed; Fadi G Lakkis
Journal:  Immunogenetics       Date:  2022-01-16       Impact factor: 2.846

4.  The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia.

Authors:  Enrico Brunetta; Manuela Fogli; Stefania Varchetta; Luisa Bozzo; Kelly L Hudspeth; Emanuela Marcenaro; Alessandro Moretta; Domenico Mavilio
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

Review 5.  Involvement of activating NK cell receptors and their modulation in pathogen immunity.

Authors:  Francesco Marras; Federica Bozzano; Andrea De Maria
Journal:  J Biomed Biotechnol       Date:  2011-08-11

Review 6.  CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution.

Authors:  Andrea De Maria; Andrea Cossarizza
Journal:  J Transl Med       Date:  2011-06-16       Impact factor: 5.531

7.  Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection.

Authors:  Donald D Anthony; Sara J Conry; Kathy Medvik; M R Sandhya Rani; Yngve Falck-Ytter; Ronald E Blanton; Michael M Lederman; Benigno Rodriguez; Alan L Landay; Johan K Sandberg
Journal:  J Infect Dis       Date:  2012-07-10       Impact factor: 7.759

8.  Persistence of pathological distribution of NK cells in HIV-infected patients with prolonged use of HAART and a sustained immune response.

Authors:  Mario Frias; Antonio Rivero-Juarez; Ana Gordon; Angela Camacho; Sara Cantisan; Francisca Cuenca-Lopez; Julian Torre-Cisneros; Jose Peña; Antonio Rivero
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 9.  Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.

Authors:  Dongfang Liu; Shuo Tian; Kai Zhang; Wei Xiong; Ndongala Michel Lubaki; Zhiying Chen; Weidong Han
Journal:  Protein Cell       Date:  2017-05-09       Impact factor: 14.870

10.  Identification of GAD65 AA 114-122 reactive 'memory-like' NK cells in newly diagnosed Type 1 diabetic patients by HLA-class I pentamers.

Authors:  Valentina Perri; Elena Gianchecchi; Loredana Cifaldi; Marsha Pellegrino; Ezio Giorda; Marco Andreani; Marco Cappa; Alessandra Fierabracci
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.